IL17A and neoplasm: Additional studies are warranted to investigate whether RORγ activators or a low dose of IL-17A can be used for boosting clinical response to neoadjuvant chemotherapy or PD-1 blockade treatment in patients who have a “cold tumor” and normally do not respond to these treatments.